CPRX (Catalyst Pharmaceutical Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by CPRX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-17 | Molly Harper | Director | D | — | — |
| 2026-07-17 | Richard J Daly | President and CEO | D | — | — |
| 2026-07-17 | William T. Andrews | Chief Medical Officer | D | — | — |
| 2026-07-17 | DONALD A DENKHAUS | Director | D | — | — |
| 2026-07-17 | Steve Miller | Chief Op. & Scientific Officer | D | — | — |
| 2026-07-17 | Gregg Russo | Chief HR Officer | D | — | — |
| 2026-07-17 | David S Tierney | Director | D | — | — |
| 2026-07-17 | Preethi Sundaram | Chief Strategy Officer | D | — | — |
| 2026-07-17 | Jeffrey Del Carmen | Chief Commercial Officer | D | — | — |
| 2026-07-17 | Michael Wayne Kalb | Chief Financial Officer | D | — | — |
| 2026-07-17 | Tamar Thompson | Director | D | — | — |
| 2026-07-17 | Daniel J. Curran | Director | D | — | — |
| 2026-07-17 | PATRICK J MCENANY | Director | D | — | — |
| 2026-07-17 | Brian Elsbernd | Chief Legal Officer | D | — | — |
| 2026-06-05 | William T. Andrews | Chief Medical Officer | MIXED | — | — |
| 2026-02-19 | Gregg Russo | Chief HR Officer | MIXED | — | — |
| 2026-01-06 | Richard J Daly | President and CEO | MIXED | — | — |
| 2026-01-06 | Michael Wayne Kalb | Executive Vice President & CFO | MIXED | — | — |
| 2025-12-30 | Steve Miller | Chief Op. & Scientific Officer | M | — | — |
| 2025-12-30 | PATRICK J MCENANY | Director | MIXED | — | — |
| 2025-12-30 | DONALD A DENKHAUS | Director | M | — | — |
| 2025-12-30 | Molly Harper | Director | M | — | — |
| 2025-12-30 | David S Tierney | Director | M | — | — |
| 2025-12-30 | Preethi Sundaram | Chief Strategy Officer | MIXED | — | — |
| 2025-12-30 | Brian Elsbernd | Chief Compliance/Legal Officer | MIXED | — | — |
| 2025-12-30 | Richard J Daly | President and CEO | MIXED | — | — |
| 2025-12-30 | Jeffrey Del Carmen | Chief Commercial Officer | MIXED | — | — |
| 2025-12-16 | Molly Harper | Director | MIXED | — | — |
| 2025-12-10 | Steve Miller | Chief Op. & Scientific Officer | M | — | — |
| 2025-12-10 | David S Tierney | Director | M | — | — |
| 2025-12-10 | Tamar Thompson | Director | M | — | — |
| 2025-12-10 | Brian Elsbernd | Chief Compliance/Legal Officer | MIXED | — | — |
| 2025-12-10 | DONALD A DENKHAUS | Director | M | — | — |
| 2025-12-10 | Molly Harper | Director | M | — | — |
| 2025-12-10 | Preethi Sundaram | Chief Strategy Officer | MIXED | — | — |
| 2025-12-10 | Jeffrey Del Carmen | Chief Commercial Officer | MIXED | — | — |
| 2025-12-10 | PATRICK J MCENANY | Director | M | — | — |
| 2025-12-03 | PATRICK J MCENANY | Director | G | — | — |
| 2025-11-28 | Jeffrey Del Carmen | Chief Commercial Officer | MIXED | — | — |
| 2025-11-24 | William T. Andrews | Chief Medical Officer | A | — | — |
| 2025-11-24 | Daniel J. Curran | Director | A | — | — |
| 2025-11-24 | Molly Harper | Director | M | — | — |
| 2025-11-24 | Michael Wayne Kalb | Executive Vice President & CFO | MIXED | — | — |
| 2025-11-24 | Gregg Russo | Chief HR Officer | A | — | — |
| 2025-11-24 | David S Tierney | Director | M | — | — |
| 2025-11-24 | Brian Elsbernd | Chief Compliance/Legal Officer | MIXED | — | — |
| 2025-11-24 | Tamar Thompson | Director | M | — | — |
| 2025-11-24 | Preethi Sundaram | Chief Strategy Officer | MIXED | — | — |
| 2025-11-24 | Steve Miller | Chief Op. & Scientific Officer | M | — | — |
| 2025-11-24 | DONALD A DENKHAUS | Director | M | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 6,666,667 | — |
| — | Director | 2,638,268 | — |
| — | Director | 732,470 | — |
| — | Director | 568,368 | — |
| — | Director | 228,887 | — |
| — | Director | 145,922 | — |
| — | VP, Regulatory Operations | 134,131 | — |
| — | Chief Med. & Reg. Officer | 68,873 | — |
| — | VP, Treasurer and CFO | 55,813 | — |
| — | EVP, Chief Commercial Officer | 44,700 | — |
| — | V.P., Treasurer & CFO | 14,493 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CPRX quote page; the site-wide leaderboard is on the insider transactions hub.